ArticleJournal of immunotherapy and precision oncology2023

Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer.

Cláudia Vieira et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.